| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4720 | Ship-2a | Cystathione gamma lyase (CSE) inhibitor, inhibiting H2S production and L-cysteine-induced relaxation of rat aortic rings ex vivo |
|
| DCC4721 | Showdomycin | Antineoplastic antibiotic |
|
| DCC4722 | Shp2 Inhibitor C21 | Inhibitor of shp2 protein tyrosine phosphatase (PTP) |
|
| DCC4723 | Shr0687 | Highly Potent and Peripheral Nervous System-Restricted KOR Agonist |
|
| DCC4724 | Sibopirdine | Novel cognitive enhancer; Nootropic agent |
|
| DCC4725 | Sid-24784551 | Novel direct HIV-1 Nef antagonist with antiretroviral activity |
|
| DCC4726 | Sid-7977382 | Novel Complement Factor C1 Inhibitor |
|
| DCC4727 | Silagaba132 | Silicon-Containing GABA Derivative, Treating Neuropathic Pain without Central-Nervous-System-Related Side Effects |
|
| DCC4728 | Silagaba161 | Silicon-Containing GABA Derivative, Treating Neuropathic Pain without Central-Nervous-System-Related Side Effects |
|
| DCC4729 | Sila-ibuprofen | Novel COX-I and COX-II inhibitor with four times higher solubility in physiological media and a lower melting enthalpy than ibuprofen |
|
| DCC4730 | Simfibrate | Peroxisome proliferator |
|
| DCC4731 | Sinapine Sulfate | Antioxidant and antimicrobial agent, counteracting mitochondrial oxidative stress in cardiomyocytes |
|
| DCC4732 | Sipi-6360 | Novel D2/5-HT2A Receptor Dual Antagonist |
|
| DCC4733 | Sipi-7623 | Novel farnesoid X receptor antagonist |
|
| DCC4734 | Sirt1-a2 | Novel SIRT1 Activator |
|
| DCC4735 | Sirt1-enhancer-a03 | First-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, normalizing sirtuin 1 levels and improving cognition in an Alzheimer's disease mouse model |
|
| DCC4736 | Sirt1-i5 | Novel SIRT1 Inhibitor, showing potent effect on prostate cancer cell line |
|
| DCC4737 | Sirt1-in-4bb | Novel SIRT1 inhibitor, inducing apoptosis in HCT116 human colon carcinoma cells partially by activating p53 |
|
| DCC4738 | Sirt2-in-6f | Potent and selective inhibitor of SIRT2 |
|
| DCC4739 | Sirt3 Inhibitor P6 | Novel selective SIRT3 inhibitor, exhibiting SIRT3 inhibitory selectivity with IC50 value of 7.2 µM over SIRT1 (32.6 µM) and SIRT2 (33.5 µM), showing potent inhibitory activity against a group of MLLr leukemic cell lines |
|
| DCC4740 | Sir-tz | Novel in situ tetrazine ligation reactive silicon-rhodamine dye |
|
| DCC4741 | Sitafloxacin | Potent broad spectrm fluoroquinolone antibiotic |
|
| DCC4742 | Sitafloxacin Monohydrate | Fluoroquinolone antibiotic, acting as antibacterial, antineoplastic, anti-Infective agents, Inhibiting DNA-gyrase and topoisomerase |
|
| DCC4743 | Si-w052 | Novel inhibitor of lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α and interleukin (IL)-6 on microglia, exhibiting anti-inflammatory activity through ER-stress-mediated autophagy, significantly inducing the conversion ratio of LC3 II/I and |
|
| DCC4744 | Sj1008066 | Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interactionm being cell permeable and having improved activity in the TR-FRET assay (IC50 0.13 µM) |
|
| DCC4745 | Sj3366 | Unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), also inhibiting HIV-2 |
|
| DCC4746 | Sj521054 | Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interaction (IC50 0.40 μM) |
|
| DCC4747 | Sj572710 | Novel Inhibitor of the Disordered Protein, p27(Kip1) |
|
| DCC4748 | Sj-bis | Novel selective MDMX antagonist |
|
| DCC4749 | Sjf-0628 | Novel BRAF-targeting PROTAC, inducing efficient and potent degradation of mutant BRAF but sparing BRAFWT, inhibiting cell growth in mutant-BRAF driven cancer cells |
|
